Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Non-cash Items (2018 - 2025)

Crinetics Pharmaceuticals has reported Non-cash Items over the past 8 years, most recently at $81.3 million for Q2 2025.

  • Quarterly results put Non-cash Items at $81.3 million for Q2 2025, up 1302.03% from a year ago — trailing twelve months through Jun 2025 was $81.3 million (up 1302.03% YoY), and the annual figure for FY2024 was $6.5 million, down 96.91%.
  • Non-cash Items for Q2 2025 was $81.3 million at Crinetics Pharmaceuticals, down from $136.4 million in the prior quarter.
  • Over the last five years, Non-cash Items for CRNX hit a ceiling of $4.1 billion in Q4 2022 and a floor of $2834.0 in Q3 2021.
  • Median Non-cash Items over the past 5 years was $30.5 million (2021), compared with a mean of $438.2 million.
  • Biggest five-year swings in Non-cash Items: tumbled 99.99% in 2021 and later surged 979328.37% in 2022.
  • Crinetics Pharmaceuticals' Non-cash Items stood at $3.0 billion in 2021, then surged by 37.88% to $4.1 billion in 2022, then crashed by 94.91% to $209.9 million in 2023, then crashed by 96.91% to $6.5 million in 2024, then skyrocketed by 1154.48% to $81.3 million in 2025.
  • The last three reported values for Non-cash Items were $81.3 million (Q2 2025), $136.4 million (Q1 2025), and $6.5 million (Q4 2024) per Business Quant data.